Lexicon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) was the recipient of some unusual options trading on Wednesday. Stock traders purchased 1,339 put options on the stock. This is an increase of approximately 1,085% compared to the typical daily volume of 113 put options.

Lexicon Pharmaceuticals stock opened at $5.07 on Friday. Lexicon Pharmaceuticals has a 52 week low of $1.13 and a 52 week high of $8.39. The company has a debt-to-equity ratio of 1.42, a quick ratio of 8.01 and a current ratio of 8.11. The stock has a market capitalization of $544.63 million, a P/E ratio of -4.45 and a beta of 1.00. The stock has a 50-day simple moving average of $3.89 and a 200 day simple moving average of $3.83.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.80. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The business had revenue of $294.45 million during the quarter, compared to analysts’ expectations of $12.00 million. During the same quarter last year, the company posted ($0.26) earnings per share. Lexicon Pharmaceuticals’s quarterly revenue was up 4124.5% on a year-over-year basis. Research analysts forecast that Lexicon Pharmaceuticals will post 0.93 earnings per share for the current year.

In related news, Director Christopher J. Sobecki acquired 25,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was bought at an average price of $2.55 per share, for a total transaction of $63,750.00. Following the acquisition, the director now directly owns 112,493 shares of the company’s stock, valued at $286,857.15. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Lonnel Coats acquired 50,000 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was bought at an average price of $3.13 per share, with a total value of $156,500.00. Following the acquisition, the chief executive officer now directly owns 127,639 shares in the company, valued at $399,510.07. The disclosure for this purchase can be found here. Insiders acquired a total of 79,500 shares of company stock worth $235,370 in the last three months. Company insiders own 6.40% of the company’s stock.

A number of institutional investors have recently bought and sold shares of LXRX. Commonwealth Equity Services LLC grew its holdings in Lexicon Pharmaceuticals by 40.5% during the third quarter. Commonwealth Equity Services LLC now owns 16,461 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 4,746 shares during the period. Trexquant Investment LP bought a new stake in Lexicon Pharmaceuticals during the second quarter valued at $92,000. Voloridge Investment Management LLC bought a new stake in Lexicon Pharmaceuticals during the second quarter valued at $105,000. Russell Investments Group Ltd. bought a new stake in Lexicon Pharmaceuticals during the third quarter valued at $202,000. Finally, Price T Rowe Associates Inc. MD boosted its position in Lexicon Pharmaceuticals by 77.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 61,642 shares of the biopharmaceutical company’s stock valued at $388,000 after acquiring an additional 26,900 shares during the last quarter. Institutional investors and hedge funds own 96.27% of the company’s stock.

Several equities analysts have recently weighed in on the company. Zacks Investment Research cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 16th. Wedbush restated a “buy” rating and issued a $17.00 price objective on shares of Lexicon Pharmaceuticals in a report on Monday, December 2nd. BidaskClub upgraded Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 7th. G.Research cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Gabelli cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $6.45.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

See Also: What are the Benefits of Index Funds?

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.